Skip to main content
. 2023 Jan 19;18(2):185–201. doi: 10.4103/1735-5362.367797

Fig. 1.

Fig. 1

Findings for annexin V-FITC vs propidium iodide quantitation of B-CPAP cells in (A) non-treated group (RPMI as negative control) in addition to (B) B-CPAP cells treated by epirubicin (10 µg/mL), (C) epirubicin (2 µg/mL), (D) etoposide (80 µg/mL), (E) etoposide (16 µg/mL), (F) metformin (20 µg/mL) in combination with epirubicin (2 µg/mL), and (G) metformin (20 µg/mL) in combination with etoposide (16 µg/mL). FITC, Fluorescein isothiocyanate.